Firefly Neuroscience(AIFF.US)

Company Encyclopedia
View More
name
Firefly Neuroscience
AIFF.US
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc.
69.53 B
AIFF.USMarket value -Rank by Market Cap -/-

Financial Score

08/01/2026 Update
C
Health Care TechnologyIndustry
Industry Ranking25/46
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-411.76%E
    • Profit Margin-2705.87%E
    • Gross Margin37.63%B
  • Growth ScoreA
    • Revenue YoY958.11%A
    • Net Profit YoY-230.20%E
    • Total Assets YoY133.61%A
    • Net Assets YoY247.87%A
  • Cash ScoreB
    • Cash Flow Margin-3.06%D
    • OCF YoY958.11%A
  • Operating ScoreE
    • Turnover0.09E
  • Debt ScoreA
    • Gearing Ratio22.16%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    In Wednesday's after-market session, several health care stocks experienced notable price changes. Gainers included Imunon (up 8.8%), Trinity Biotech (up 7.84%), and Firefly Neuroscience (up 7.27%). Conversely, Biohaven saw a significant decline of 15.9%, while Lite Strategy and Advanced Biomed fell by 12.24% and 12.0%, respectively. The article was generated by Benzinga's automated content engine and reviewed by an editor.

    benzinga_article·
    US
    AIFF
    +4.67%
    US
    LITS
    +4.93%
    US
    TRIB
    -1.90%
    benzinga_article·
    US
    AIFF
    +4.67%
    US
    LITS
    +4.93%
    US
    TRIB
    -1.90%

    Firefly Neuroscience Announces Private Placement of New Warrants

    Firefly Neuroscience Inc. announced a private placement of new warrants, exchanging previously issued warrants from June 2025. The transaction could yield $400,000 if all new warrants are exercised, intended for working capital and corporate purposes. This announcement was made via EDGAR by Firefly Neuroscience and is for informational purposes only, not financial advice.

    Reuters·
    US
    AIFF
    +4.67%
    Reuters·
    US
    AIFF
    +4.67%

    Firefly Neuroscience Reports Third Quarter 2025 Financial Results

    Firefly Neuroscience, Inc. reported significant growth in its third quarter 2025 financial results, with revenues increasing over tenfold year-over-year to $388,000, driven by the acquisition of Evoke Neuroscience. The company also achieved a 30% sequential revenue growth and reduced operating expenses by 35%, resulting in a net loss of $2.6 million, an improvement from the previous year. Firefly's EEG/ERP scan volumes rose 10.9% sequentially, reflecting successful business integration. The company aims to continue its commercial growth strategy while leveraging advanced AI technologies for brain health solutions.

    fidelity·
    US
    AIFF
    +4.67%
    fidelity·
    US
    AIFF
    +4.67%

    Firefly Neuroscience | 10-Q: FY2025 Q3 Revenue: USD 388 K

    LB filings·
    US
    AIFF
    +4.67%
    LB filings·
    US
    AIFF
    +4.67%

    Firefly Neuroscience Approves Increase in Authorized Shares

    Firefly Neuroscience (AIFF) approved an increase in authorized shares during its annual stockholders meeting on October 27, 2025, which was finalized on October 31, 2025. This change aims to enhance the company's capital structure for future growth. However, Spark's analysis indicates that AIFF is underperforming due to significant financial instability, including persistent losses and negative equity, despite the strategic acquisition of Evoke Neuroscience. The stock is rated as a strong sell with a market cap of $25.28M and an average trading volume of 1,699,261.

    Tip Ranks·
    US
    AIFF
    +4.67%
    Tip Ranks·
    US
    AIFF
    +4.67%
    © 2026 Longbridge｜Disclaimer